Cytek Biosciences (CTKB) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChartTranscripts

CTKB Stock Forecast


Cytek Biosciences (CTKB) stock forecast, based on 4 Wall Street analysts, predicts a 12-month average price target of $6.63, with a high of $8.00 and a low of $5.25. This represents a 84.17% increase from the last price of $3.60.

$3 $4 $5 $6 $7 $8 $9 $10 High: $8 Avg: $6.63 Low: $5.25 Last Closed Price: $3.6

CTKB Stock Rating


Cytek Biosciences stock's rating consensus is Buy, based on 4 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 2 Buy (50.00%), 1 Hold (25.00%), 1 Sell (25.00%), and 0 Strong Sell (0.00%).

Buy
Total 4 0 1 1 2 Strong Sell Sell Hold Buy Strong Buy

CTKB Price Target Upside V Benchmarks


TypeNameUpside
StockCytek Biosciences84.17%
SectorHealthcare Stocks 19.91%
IndustryMedical Device Stocks18.37%

Price Target Trends


1M3M12M
# Anlaysts--2
Avg Price Target--$6.63
Last Closing Price$3.60$3.60$3.60
Upside/Downside--84.17%
Ratings Trends

DateStrong BuyBuyHoldSellStrong SellTotal
Jul, 25113--5
Jun, 25113-16
May, 25122-16
Apr, 25122-16
Mar, 25122-16
Analyst Price Target Forecasts

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 04, 2025Piper Sandler$8.00$4.3185.61%122.22%
Feb 02, 2025Matthew SykesGoldman Sachs$5.25$5.151.94%45.83%
May 13, 2024Dave WestenbergPiper Sandler$8.50$6.1538.21%136.11%
Aug 17, 2022David WestenbergPiper Sandler$16.00$14.0813.64%344.44%
May 15, 2022David WestenbergPiper Sandler$12.00$9.3827.93%233.33%
Analyst Rating Forecasts

DateCompanyPrevious RatingNew RatingRating Change
May 13, 2024Piper SandlerOverweightOverweighthold
Dec 14, 2023StephensPositiveinitialise
Oct 24, 2023Morgan StanleyEqual-WeightEqual-Weighthold
Aug 17, 2022Piper SandlerOverweightOverweighthold
Jul 19, 2022Piper SandlerOverweightOverweighthold
May 15, 2022Piper SandlerOverweightOverweighthold
May 12, 2022Goldman SachsBuyBuyhold

Financial Forecast


EPS Forecast

Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$0.03$0.02$-0.09-----
Avg Forecast$0.11$0.09$-0.03$0.10$0.15$0.20$0.18$0.24
High Forecast$0.11$0.09$-0.02$0.13$0.16$0.41$0.19$0.25
Low Forecast$0.10$0.09$-0.05$0.08$0.13$0.06$0.17$0.23
Surprise %-72.73%-77.78%200.00%-----

Revenue Forecast

$100M $150M $200M $250M $300M $350M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$127.95M$164.04M$193.01M$111.11M----
Avg Forecast$125.42M$166.42M$190.85M$202.99M$220.85M$243.98M$288.70M$317.00M
High Forecast$128.52M$170.68M$198.96M$203.91M$223.08M$247.92M$297.30M$326.45M
Low Forecast$122.77M$161.00M$182.74M$202.52M$216.83M$240.04M$277.52M$304.72M
Surprise %2.02%-1.43%1.13%-45.26%----

Net Income Forecast

$-15M $0 $15M $30M $45M $60M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$4.42M$2.58M$-12.15M-----
Avg Forecast$14.54M$12.18M$-4.51M$14.04M$20.21M$32.08M$24.35M$32.47M
High Forecast$15.01M$12.58M$-2.71M$17.28M$22.16M$55.60M$25.29M$33.73M
Low Forecast$14.14M$11.66M$-6.31M$10.80M$18.25M$8.55M$23.13M$30.83M
Surprise %-69.63%-78.84%169.39%-----

CTKB Forecast FAQ


Is Cytek Biosciences stock a buy?

Cytek Biosciences stock has a consensus rating of Buy, based on 4 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 2 Buy, 1 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Cytek Biosciences is a favorable investment for most analysts.

What is Cytek Biosciences's price target?

Cytek Biosciences's price target, set by 4 Wall Street analysts, averages $6.63 over the next 12 months. The price target range spans from $5.25 at the low end to $8 at the high end, suggesting a potential 84.17% change from the previous closing price of $3.6.

How does Cytek Biosciences stock forecast compare to its benchmarks?

Cytek Biosciences's stock forecast shows a 84.17% upside, outperforming the average forecast for the healthcare stocks sector (19.91%) and outperforming the medical device stocks industry (18.37%).

What is the breakdown of analyst ratings for Cytek Biosciences over the past three months?

  • July 2025: 20.00% Strong Buy, 20.00% Buy, 60.00% Hold, 0% Sell, 0% Strong Sell.
  • June 2025: 16.67% Strong Buy, 16.67% Buy, 50.00% Hold, 0% Sell, 16.67% Strong Sell.
  • May 2025: 16.67% Strong Buy, 33.33% Buy, 33.33% Hold, 0% Sell, 16.67% Strong Sell.

What is Cytek Biosciences’s EPS forecast?

Cytek Biosciences's average annual EPS forecast for its fiscal year ending in December 2025 is $0.15, marking a 0% decrease from the reported $0 in 2024. Estimates for the following years are $0.2 in 2026, $0.18 in 2027, and $0.24 in 2028.

What is Cytek Biosciences’s revenue forecast?

Cytek Biosciences's average annual revenue forecast for its fiscal year ending in December 2025 is $220.85M, reflecting a 98.78% increase from the reported $111.11M in 2024. The forecast for 2026 is $243.98M, followed by $288.7M for 2027, and $317M for 2028.

What is Cytek Biosciences’s net income forecast?

Cytek Biosciences's net income forecast for the fiscal year ending in December 2025 stands at $20.21M, representing a 0% decrease from the reported $0 in 2024. Projections indicate $32.08M in 2026, $24.35M in 2027, and $32.47M in 2028.